elhamkhani
/
Test2
/
Login
Register
TriplyDB
Test2
Browser
Triples
Insights
Schema
BETA
Class frequency
Class hierarchy
SPARQL
GraphQL
BETA
Graphs
1
Q35880396-6FEC4AB9-A545-4918-AF63-7C1F51E4D86F
Q35880396-6FEC4AB9-A545-4918-AF63-7C1F51E4D86F
BestRank
Statement
http://www.wikidata.org/entity/statement/Q35880396-6FEC4AB9-A545-4918-AF63-7C1F51E4D86F
Review article: aminosalicylates in inflammatory bowel disease.
P2860
Q35880396-6FEC4AB9-A545-4918-AF63-7C1F51E4D86F
BestRank
Statement
http://www.wikidata.org/entity/statement/Q35880396-6FEC4AB9-A545-4918-AF63-7C1F51E4D86F
rank
NormalRank
type
BestRank
Statement
wasDerivedFrom
5e61e56ad9b5d7cc45e489ab938ddf6fe014737a
P2860
A randomized, double blind, dose-response comparison of balsalazide (6.75 g), balsalazide (2.25 g), and mesalamine (2.4 g) in the treatment of active, mild-to-moderate ulcerative colitis.